PHARMACOECONOMIC STUDY OVER USE OF ANTICHOLINERGIC BRONCHODILATORS (SPIRIVA AND ATROVENT) FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Currently, chronic obstructive pulmonary disease (COPD) is a 5-largest cause of death worldwide, and the reduced activities of daily living, productivity and disability explain a significant economic and social damage. World Health Organization (WHO) predicts, that COPD will be a 3-largest cause of...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2015-03-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/37 |